US Stock MarketDetailed Quotes
CRBU Caribou Biosciences
- 1.680
- +0.090+5.66%
Close Jan 2 16:00 ET
- 1.720
- +0.040+2.38%
Post 20:01 ET
152.13MMarket Cap-1.01P/E (TTM)
1.775High1.610Low1.36MVolume1.640Open1.590Pre Close2.30MTurnover1.67%Turnover RatioLossP/E (Static)90.55MShares8.33052wk High0.54P/B137.05MFloat Cap1.50052wk Low--Dividend TTM81.58MShs Float32.645Historical High--Div YieldTTM10.38%Amplitude1.500Historical Low1.688Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Caribou Biosciences Stock Forum
$Gossamer Bio (GOSS.US)$
$Archer Aviation (ACHR.US)$
Gonna add a position for each again.
Caribou Biosciences Announces the FDA Has Granted Fast Track Designations to CB-010 in Refractory Sle and to CB-012 in Relapsed or Refractory Aml
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...
The regulator found a proposed comparator arm of platinum-based immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation to be "acceptable," the compan...
No comment yet